Three-year outcome data of second-line antiretroviral therapy in Ugandan adults: Good virological response but high rate of toxicity

Journal of the International Association of Physicians in AIDS Care

Volumn 8, Issue 1, 2009, Pages 52-59

  Castelnuovo, Barbara ^a   John, Laurence ^a   Lutwama, Fred ^a   Ronald, Allan ^b   Spacek, Lisa A ^c   Bates, Michael ^d   Kamya, Moses R ^e   Colebunders, Robert ^f  

^a MULAGO HOSPITAL   (Uganda)

^b UNIVERSITY OF MANITOBA   (Canada)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MONOGRAM BIOSCIENCES   (United States)

^e MAKERERE UNIVERSITY   (Uganda)

^f UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

resource limited settings; second line antiretroviral therapy; virological response

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; DIDANOSINE; LOPINAVIR; PYRIMIDINONE DERIVATIVE; RITONAVIR; STAVUDINE; ZIDOVUDINE;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; BLOOD; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; DRUG COMBINATION; DRUG EFFECT; DRUG TOXICITY; FEMALE; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERVIEW; MALE; PROSPECTIVE STUDY; STANDARD; TREATMENT OUTCOME; UGANDA; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; DIDANOSINE; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; DRUG TOXICITY; FEMALE; HIV; HIV INFECTIONS; HUMANS; INTERVIEWS AS TOPIC; MALE; PROSPECTIVE STUDIES; PYRIMIDINONES; RITONAVIR; STAVUDINE; TREATMENT OUTCOME; UGANDA; VIRAL LOAD; ZIDOVUDINE;

EID: 67649364115     PISSN: 15451097     EISSN: 15570886     Source Type: Journal    
DOI: 10.1177/1545109708328538     Document Type: Article

References (20)

1. Towards universal access: AIDS report. Scaling up priority HIV/AIDS interventions in the health sector: progress report 2008. Geneva: WHO, UNAIDS, UNICEF. Available at: http//www.who.int/hiv/mediacentre/2008progressreport/en/ index.html. Accessed August 10, 2008.
2. Pujades-Rodríguez M., O'Brien D., Humblet P., Calmy A. Second-line antiretroviral therapy in resource-limited settings: the experience of Médecines Sans Frontières. AIDS. 2008 ; 22: 1305-1312.
3. WHO. Global price reporting mechanism. Available at: http://www.who.int/ hiv/amds/price/hdd/index.aspx. Accessed 20, August 2008.
4. Consultation on Technical and Operational Recommendations for Scale-up of Laboratory Services and Monitoring HIV Antiretroviral Therapy in Resource-limited Settings. Geneva: World Health Organization ; 2006.
5. WHO. Antiretroviral Therapy for HIV Infection in Adults and Adolescents in Resource-limited Settings: Towards Universal Access. Geneva: WHO ; 2006. Available at: http://www.who.int/hiv/pub/guidelines/art/en/index.html. Accessed May 5, 2008.
6. Sungkanuparph S., Manosuthi W., Kiertiburanakul S., Piyavong B., Chumpathat N., Chantratita1 W. Options for a second-line antiretroviral regimen for HIV Type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. Clin Infect Dis. 2007 ; 44: 447-452. (Pubitemid 46147631)
7. Renaud-Thery F., Nguimfack BD, Vitoria M., et al. Use of antiretroviral therapy in resource-limited countries in 2006: distribution and uptake of first- and second-line regimens. AIDS. 2007 ; 21 (suppl 4). S89 - S95.
8. 1st ed National Antiretroviral treatment and Care Guidelines for Adults and Children. Republic of Uganda, Uganda: Ministry of health ; 2003.
9. Spacek L., Shibab H., Kamya M., et al. Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda. Clin Infect Dis. 2006 ; 42: 252-259. (Pubitemid 43054199)
10. Arribas J., Pulido F., Delgado R., et al. Lopinavir/ritonavir as single-drug maintenance therapy in patients with HIV-1 viral suppression: forty eight week results of a randomized, controlled, open label, proof of concept pilot clinical trial (OK04 Study). J Acquir Immune Defic Syndr. 2005 ; 40: 280-287.
11. Campo RE, Lalanne R., Tanner T., et al. Lopinavir/ritonavir maintenance monotherapy after successful viral suppression with standard highly active antiretroviral therapy in HIV-1-infected patients. AIDS. 2005 ; 19: 447-449. (Pubitemid 40446194)
12. Pateson D., Swindells S., Mohr J., et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000 ; 133: 21-30. (Pubitemid 30432540)
13. McNabb J., Ross JW, Abriola K., Turley C., Nightingale CH, Nicolau DP Adherence to highly active antiretroviral therapy predict virologic outcome at an inner-city immunodeficiency virus clinic. Clin Infect Dis. 2001 ; 33: 700-705. (Pubitemid 32762944)
14. Oyugi JH, Byakika-Tusiime J., Charlebois ED, et al. Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting. J Acquir Immune Defic Syndr. 2004 ; 36: 1100-1102. (Pubitemid 38989377)
15. Kiguba R., Byakika-Tusiime J., Karamagi C., Ssali F., Mugyenyi P., Katabira E. Discontinuation and modification of highly active antiretroviral therapy in HIV-infected Ugandans: prevalence and associated factors. J Acquir Immune Defic Syndr. 2007 ; 45: 218-223. (Pubitemid 46869816)
16. Forna F., Liechty CA, Solberg P., et al. Clinical toxicity of highly active antiretroviral therapy in a home-based AIDS care program in rural Uganda. J Acquir Immune Defic Syndr. 2007 ; 44: 456-462. (Pubitemid 46555382)
17. Songa PM, Castelnuovo B., Mugasha EB, Ocama P., Kambugu A. Symptomatic hyperlactatemia associated with nucleoside analogue reverse-transcriptase inhibitor use in HIV-infected patients: a report of 24 cases in a resource-limited setting (Uganda). Clin Infect Dis. 2007 ; 45: 514-517. (Pubitemid 47204473)
18. Wester CW, Okezie OA, Thomas AM, et al. Higher-than-expected rates of lactic acidosis among highly active antiretroviral therapy-treated women in Botswana: preliminary results from a large randomized clinical trial. J Acquir Immune Defic Syndr. 2007 ; 46: 318-322. (Pubitemid 350287359)
19. Rosen S., Long L., Fox M., Sanne I. Cost and cost-effectiveness of switching from stavudine to tenofovir in first line antiretroviral regimens in South Africa. J Acquir Immune Defic Syndr. 2008 ; 48: 334-343.
20. Gupta RK, Hill A., Sawyer W., Pillay D. Drug resistance after virological failure on first-line HAART in resource rich and poor settings: a meta-analysis. XV Conference Presented at CROI 2008; February 3-6, 2008 ; Boston, MA. Abstract 891.